Detail akcie ImageneBio Rg online

Business Summary: ImageneBio, Inc., formerly Ikena Oncology, Inc., is a clinical-stage biotechnology company. The Company is focused on developing disease-modifying treatments for immunological/autoimmune and inflammatory (I&I) diseases. The Company develops differentiated profiles that can effectively control and change the course of I&I diseases for affected patients, treat their symptoms, and improve quality of life. The Company’s lead asset is IMG-007, a novel non-depleting anti-OX40 mAb bioengineered with Fc N297A mutations to abolish antibody-dependent cellular cytotoxicity (ADCC). IMG-007 is designed to specifically bind to OX40 on activated T cells and block the interaction between OX40 and OX40L without killing the T cells. The Company is conducting a Phase 2b clinical trial of IMG-007 in patients with moderate-to-severe atopic dermatitis.
Financial Summary: BRIEF: For the nine months ended 30 September 2025, ImageneBio Inc revenues was not reported. Net loss applicable to common stockholders decreased 8% to $37M. Lower net loss reflects Research and development decrease of 73% to $6.8M (expense), Other income (expense) increase from $640K to $7.3M (income), General and administrative - Balancing decrease of 33% to $9.1M (expense).